in

Bernie Sanders Slams ‘Outrageous’ Prices Of Miracle Weight Loss Drug Ozempic, Mulls Meeting With Novo Nordisk CEO – Novo Nordisk (NYSE:NVO)

Bernie Sanders Slams ‘Outrageous’ Prices Of Miracle Weight Loss Drug Ozempic, Mulls Meeting With Novo Nordisk CEO – Novo Nordisk (NYSE:NVO)
Announcement



“Benzinga’s Top Stocks to Buy Today”

There’s only two mistakes you can make when investing. One is not investing at all. The next is buying the wrong stocks. Get an edge on which stocks to buy with the Benzinga Insider Report, our best weekly stock report sent right to your inbox. Act fast and secure our top stock picks at an unbelievable discount! Claim This Limited $0.99 Offer NOW!


Sen. Bernie Sanders (I-Vt.) has taken a stand against the “outrageous” prices of diabetes drug Ozempic by Novo Nordisk (NYSE:NVO). He is considering hearings on the issue and is seeking a meeting with the company’s CEO to discuss reducing the drug’s price.

What Happened: Sanders, who chairs the Senate Health, Education, Labor, and Pensions (HELP) Committee, is concerned about the high cost of Ozempic.

ENTER TO WIN $500 IN STOCK OR CRYPTO

Enter your email and you’ll also get Benzinga’s ultimate morning update AND a free $30 gift card and more!

Ozempic is sometimes used controversially for weight loss by suppressing appetite.

He plans to meet with ‘Miracle’ weight loss drug maker’s CEO, Lars Fruergaard Jørgensen, to discuss lowering the list prices of the drug.

“This outrageously high price has the potential to bankrupt Medicare, the American people and our entire health care system.”

“We cannot allow that to happen.”

The senator’s decision was influenced by a recent study published in the JAMA Network, which suggested that the manufacturing cost of Ozempic is significantly lower than its current price.

Sanders highlighted that the drug costs less than $5 a month to produce, yet it is sold for nearly $1,000 a month in the U.S.


FREE REPORT: How To Learn Options Trading Fast

In this special report, you will learn the four best strategies for trading options, how to stay safe as a complete beginner, ​a 411% trade case study, PLUS how to access two new potential winning options trades starting today.Claim Your Free Report Here.


Novo Nordisk, however, has defended its pricing, stating that most U.S. patients covered by commercial health plans pay $25 or less a month for their prescriptions, reported Business Insider.

Announcement

The company also emphasized its $5 billion global investment in research and development in 2023.

See Also: Bernie Sanders Blasts Big Pharma’s Pricing Of Lifesaving Drugs In US During Senate Hearing On Medicare

Sanders warned that the high price of Ozempic not only makes it unaffordable for many who need it but also poses a risk to Medicare and the entire U.S. healthcare system.

Why It Matters: The cost of Ozempic has been a topic of concern for some time. A study conducted in March revealed that the drug could be manufactured for less than $5 a month, despite being sold for nearly $1,000 a month in the U.S., but only $155 a month in Canada and $59 in Germany.

Novo Nordisk’s pricing strategy has also sparked discussions about the drug’s potential impact on the broader economy. Some, like prominent Tesla investor Ross Gerber, have suggested that using Ozempic could lead to significant cost savings.

Price Action: Novo Nordisk’s stock closed 0.35% up at $128.40 on Friday, according to Benzinga Pro.

Read Next: Bernie Sanders Calls For 32-Hour Workweek Without Pay Cut: ‘The Time Is Long Overdue’

Photos courtesy: Shutterstock


“Benzinga’s Top Stocks to Buy Today”

There’s only two mistakes you can make when investing. One is not investing at all. The next is buying the wrong stocks. Get an edge on which stocks to buy with the Benzinga Insider Report, our best weekly stock report sent right to your inbox. Act fast and secure our top stock picks at an unbelievable discount! Claim This Limited $0.99 Offer NOW!


Announcement

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.



Source link

Announcement

What do you think?

Written by Politixia

Announcement
Announcement

Leave a Reply

Your email address will not be published. Required fields are marked *

Announcement
On the Radar: Temu, ‘Deinfluencing’ and Lemon8

On the Radar: Temu, ‘Deinfluencing’ and Lemon8

Donald Trump Stoops to Lowest Low Yet With Violent Post of Biden – Mother Jones

Donald Trump Stoops to Lowest Low Yet With Violent Post of Biden – Mother Jones